MORI-BUILDING
24.11.2023 07:01:28 CET | Business Wire | Press release
Mori Building Co., Ltd., Japan’s leading urban landscape developer, today marked the official launch of Azabudai Hills, a mixed-use complex and world-class new neighborhood in central Tokyo. Embracing the concept of “Modern Urban Village – Green & Wellness”, Azabudai Hills is a nature-rich landmark with integrated urban functionalities including a top-tier business center, residential, retail, cultural, medical facilities, educational institutions and a large open space filled with lush greenery that brings people together.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20231123377497/en/
©DBOX for Mori Building Co., Ltd - Azabudai Hills (Graphic: Business Wire)
Mori Building’s vision for Azabudai Hills is to become a standard-setting 21st century "Green & Wellness" community, where people live harmoniously with nature. Spanning approximately 8.1 hectares, Azabudai Hills has a total floor area of approximately 861,700m², including 214,500m² of office space, 24,000m² of greenery, 1,400 residential units, 122 hotel rooms and around 150 retail shops and restaurants. Mori JP Tower soars to a height of 330 meters, making it the tallest building in Japan. This reimagined “city within a city” neighborhood will host approximately 20,000 office workers and 3,500 residents when fully occupied and is expected to welcome 30 million visitors per year.
“Mori Building is dedicated to creating and nurturing cities’ vitality through large-scale urban redevelopment projects,” said Shingo Tsuji, President and CEO of Mori Building Co., Ltd. “Over the years, we continue to anticipate the direction of future cities as society evolves. Major cities around the world have gone through tremendous changes in recent years. We believe that what people want from urban living in the future is to have access to integrated functionalities while being able to live in harmony with nature, to build relationships with others and to enjoy physical and mental wellbeing. We wanted to create a neighborhood that embodies these values in the heart of Tokyo. Azabudai Hills demonstrates our vision of ‘Green & Wellness’ for urban life as well as our ambition to contribute to the international competitiveness of Tokyo.”
Design Inspired by Green & Wellness
Azabudai Hills embodies Mori's vision of Modern Urban Village –Green & Wellness, a huge open space filled with lush greenery that brings people together to build a new community in the heart of Tokyo.
The architectural design of Azabudai Hills began with outlining the flow of people and a seamless landscape with a Central Green public square. Locations were then considered for the high-rise towers, enabling them to melt into the lush greenery. This is the opposite of the traditional approach of placing the buildings first.
In addition, the usage of compact high-rise towers made it possible to create a large amount of green space to the area. By aggregating numerous small plots of land and then building three skyscrapers on the site, Mori Building created a huge open space filled with greenery on the ground level. This is the basis of the Vertical Garden City concept that Mori Building has implemented across its iconic projects over the years, including ARK Hills, Roppongi Hills, and Toranomon Hills.
Azabudai Hills brings people closer to nature with some 320 diverse species of plants that transform the space at each season. An orchard of approximately 200 m² will be located on a sloping green space with 11 types of fruit trees, providing urban dwellers with the rare opportunity to witness nature’s wonder.
Public art installations throughout the complex create an urban space, in which art and nature blend seamlessly and people can visualize their connection with the natural world. Azabudai Hills Gallery will be the core cultural promotion facility in Azabudai Hills, a development based on the concept that the “entire city is a museum”.
Top architecture and design teams including Pelli Clarke & Partners and Heatherwick Studio came together to create a landmark that is distinctively Japanese on the one hand by tapping into local aesthetic, topographical, and seasonal elements, while offering a new framework of urban living focused on greenery, wellness and harmony with nature that has wider applications.
“Cities are among the greatest inventions of mankind and Azabudai Hills has propelled their evolution forward dramatically, interweaving architecture, nature and community. Working directly with Mr. Minoru Mori and Mr. Shingo Tsuji, we have created an active, diverse and humane city-within-a-city,” said Fred Clarke, Co-Founder and Partner of Pelli Clarke & Partners. “With its citizens top of mind, Mori Building and the design team seek to contribute to the art and science of building our urban future. It is an honor for us to have shared their decades-long vision!”
“We were inspired to create a district that connects with people’s emotions in a different way,” said Thomas Heatherwick, Founder of Heatherwick Studio. “By combining cultural and social facilities with an extraordinary three-dimensional, explorable landscape, it’s been possible to offer visitors and the local community somewhere to connect with each other and enjoy open green public spaces. This is a joyful and unique public place for Tokyo, designed to be cherished for many years.”
Home for Leading Business and Global Institutions
Azabudai Hills has garnered support from partners who share the vision of Green & Wellness. Among these prestigious partners are the Keio University Center for Preventive Medicine; The British School in Tokyo, one of the largest international schools in the city center; Janu Tokyo, the world debut of Aman's sibling brand and the only hotel in the development; Aman Residences, Tokyo, delivering an entirely new standard of living with just 91 units offering the fully-serviced Aman branded lifestyle; the Tokyo Venture Capital Hub, bringing together over 70 Japanese venture capitals; around 150 retail stores, including world-class luxury brands; Azabudai Hills Market, which promotes authentic Japanese food culture; and the renowned MORI Building DIGITAL ART MUSEUM: EPSON teamLab Borderless, previously located in Odaiba, Tokyo. Many of these exceptional establishments have opened in Azabudai Hills with additional facilities to open after December 2023.
Upcoming Launch schedule
- Late January 2024 - Azabudai Hills Market
- Early February 2024 - MORI Building Digital Art Museum: EPSON teamLab Borderless
- February 2024 - Janu Tokyo
- From February 2024 - Garden Plaza (luxury brands)
35 Years in the Making
The Azabudai Hills project began in 1989 with the establishment of the Council of Redeveloping Cities. The project site encompasses a long, narrow district, broken up by hills and valleys with a complex terrain. Prior to redevelopment, the fragmented district was populated with small, wooden houses and buildings that needed major infrastructure upgrades and urban function improvements.
Since then, Mori Building Co. worked in collaboration with some 300 landowners of diverse backgrounds for nearly 35 years to bring Azabudai Hills to life. The project received overwhelming support from landowners and local constituents. In 2017, the City Plan was approved, and construction began in August 2019.
“I am turning 99 years old this December and the Azabudai Hills project started when I was in my mid-60s. We took a thoughtful approach to make sure that everyone was on board with the new development plan. Once that was decided, it moved forward so quickly that it’s hard to believe that we are already at the finish line. Mori Building played an instrumental role in leading the redevelopment and making this unprecedented project a reality,” said Kenichi Magatani, Chair of the Azabudai Hills Urban Redevelopment Association.
“I have lived in this neighborhood for a long time, but I have never seen such a dynamic urban development project at the heart of the city. I am sure that people will be amazed by not just the spectacular high-rise towers, but also by its rich greenery, and the incredible amenities including markets and restaurants, retail shops, museums, medical center, and international school. I strongly believe that this revitalized neighborhood is something Tokyo and Japan can be proud of for decades to come,” said Magatani.
Facilitate Innovation/VC Ecosystem
Azabudai Hills is the home for Tokyo Venture Capital Hub (TVCH), the first large-scale venture capital hub in Japan. TVCH is designed to foster homegrown start-ups, exchange business ideas between VCs, and entrepreneurs, and create an ecosystem that revitalizes Japan’s innovation economy.
Located on the 4th and 5th floors of Garden Plaza B, TVCH offers best-in-kind office space and a co-working area that facilitate investment pitches, seminars, workshops, and networking events. TVCH will host some 70 corporate VCs and top independent VCs including Drone Fund, Incubate Fund, Spiral Capital, as well as Japan Venture Capital Association and University of Tokyo Edge Capital Partners (UTEC).
In addition, start-ups, VCs, and corporations at TVCH are encouraged to team up with collaborators at other innovation incubators, such as ARCH and CIC Tokyo, and Japan Innovation Campus in Silicon Valley, that are located within other Mori properties in Japan and overseas.
Leader in Sustainability
Azabudai Hills is a leader in promoting citywide efforts to decarbonize and recycle resources. From the time construction is completed, 100% of the electricity supplied to the complex will come from renewable sources, meeting the targets set by the Renewable Energy 100% (RE100) international environmental initiative led by the UK’s Climate Group. AI technology will be deployed in the energy center to optimize the management of this large complex’s mixed-use energy consumption.
In addition, Azabudai Hills will deploy measures across the complex to reduce environmental impact including usage of alternative energy, reusing stormwater for watering the greenery and horizontal plastic recycling.
Azabudai Hills is on track to receive several prestigious environmental distinctions, including the highest-level LEED Neighborhood Development certification for mixed-use developments, LEED’s BD+C (Building Design/Core and Shell Development) certification as well as WELL certification.
A factbook providing full details of Azabudai Hills and its facilities is available at the following website:
https://onl.tw/VYcx5TJ
Mori Building is an innovative urban developer based in Tokyo. The company is committed to maximizing the magnetic power of cities by creating and nurturing safe, sustainable, and cosmopolitan urban centers based on its unique Vertical Garden City concept of high-rise centers for business, education, leisure, and residence. The concept is applied in the company’s many leading-edge projects, including ARK Hills, Roppongi Hills, and Toranomon Hills in Tokyo and the Shanghai World Financial Center. Mori Building is also engaged in real estate leasing, project management, and consultation. Please visit www.mori.co.jp/en
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20231123377497/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital18.9.2026 11:48:00 CEST | Press release
Estithmar Holding Q.P.S.C. announced the completion of the transfer of a 48.68% stake in Shahba Bank to Masaref Holding LLC, subsidiary of Estithmar Capital, Estithmar Holding’s financial services and investments arm. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918807909/en/ Estithmar Holding Announces Completion of 48.68% Stake Transfer in Shahba Bank to Masaref Holding, a Subsidiary of Estithmar Capital (Photo: AETOSWire) As a shareholder, Masaref Holding intends to support the assessment of proposals aimed at strengthening Shahba Bank’s financial, operational and technological capabilities, including potential capital enhancement, branch network expansion, and the development of products and services for individuals, businesses and SMEs. The proposals may include modernizing banking and operational systems, develop digital services, and strengthen governance, compliance, risk management and cybersecurity to enhance
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
